Clinical Trials · NCT07871799

ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging

CompletedPhase 2Semaglutide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Sheba Medical Center
Enrollment
31
Start date
Nov 2025
Locations
1 site, Israel
Primary endpoint
Change From Baseline in Muscular-Immune-Cognitive Composite (MIC-C) Score at Week 8
View Semaglutide compound reference